Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-05-21

Inovio Pharmaceuticals (INO)

CEO Jacqueline Shea was paid $1,587,155 in fiscal year 2025, ↓ down 22.6% from fiscal year 2024, the 20th percentile of its disclosed peer group (SEC filing 0001055726-26-000011 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,587,155 ↓
Jacqueline Shea total, FY2025
20th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
91.19%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

INO's next annual pay disclosure, estimated April 7, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jacqueline Shea$728,000$0$346,101$351,955$144,144$0$16,955$1,587,155
President, Chief Executive Officer and Director
Michael Sumner548,7080127,607129,55487,392017,375910,636
Chief Medical Officer and Head of Development
Peter Kies514,6040117,479117,92768,236015,438833,684
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Jacqueline Shea$1,587,155$2,050,669$2,438,908↓ −463,514
Michael Sumner910,6361,037,406—↓ −126,770
Peter Kies833,684940,0721,161,040↓ −106,388

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Inovio Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper INO reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against INO
5 companies name INO as a compensation peer

The list of companies that name INO as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Peter KiesCFO$833,684
Jacqueline SheaCEO$1,587,155
Michael SumnerExecutive$910,636
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Ann C. MillerIndependent Director$91,750
David B. WeinerIndependent Director$52,500
Jay P. ShepardIndependent Director$80,000
Lota S. ZothIndependent Director$77,500
Roger D. DanseyIndependent Director$72,095
Simon X. BenitoChair of the Board$117,500
Wendy L. YarnoIndependent Director$82,500
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jacqueline Elizabeth SheaDirector2026-05-15D7,717$1$10,032CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-15D2,38500Derivative, Class A CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-15D6801884CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-15A2,385——CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-15D4,77100Derivative, Class A CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-15D1,71212,226CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-15A4,771——CommonForm 4 ↗
Peter KiesCFO2026-05-15D4,77100Derivative, Class A CommonForm 4 ↗
Peter KiesCFO2026-05-15D2,57113,342CommonForm 4 ↗
Peter KiesCFO2026-05-15A4,771——CommonForm 4 ↗
Jacqueline Elizabeth SheaDirector2026-05-15D17,74400Derivative, Class A CommonForm 4 ↗
Jacqueline Elizabeth SheaDirector2026-05-15A17,744——CommonForm 4 ↗
Jacqueline Elizabeth SheaDirector2026-05-20A100,24000Derivative, Class A CommonForm 4 ↗
Jacqueline Elizabeth SheaDirector2026-05-20A123,76000Derivative, Class A CommonForm 4 ↗
Jacqueline Elizabeth SheaDirector2026-05-20D28,29600Derivative, Class A CommonForm 4 ↗
Jacqueline Elizabeth SheaDirector2026-05-20D12,306115,136CommonForm 4 ↗
Jacqueline Elizabeth SheaDirector2026-05-20A28,296——CommonForm 4 ↗
Peter KiesCFO2026-05-20D8,70000Derivative, Class A CommonForm 4 ↗
Peter KiesCFO2026-05-20D4,68815,766CommonForm 4 ↗
Peter KiesCFO2026-05-20A8,700——CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-20A46,87600Derivative, Class A CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-20D9,45000Derivative, Class A CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-20D2,69313,312CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-20A9,450——CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-20A34,16000Derivative, Class A CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-20D6,02700Derivative, Class A CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-20D2,16312,660CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-20A6,027——CommonForm 4 ↗
Simon X. BenitoDirector2026-05-20A34,20000Derivative, Class A CommonForm 4 ↗
Simon X. BenitoDirector2026-05-20A41,80000Derivative, Class A CommonForm 4 ↗
Roger D. DanseyDirector2026-05-20A34,20000Derivative, Class A CommonForm 4 ↗
Roger D. DanseyDirector2026-05-20A41,80000Derivative, Class A CommonForm 4 ↗
Lota S. ZothDirector2026-05-20A34,20000Derivative, Class A CommonForm 4 ↗
Lota S. ZothDirector2026-05-20A41,80000Derivative, Class A CommonForm 4 ↗
David B. WeinerDirector2026-05-20A34,20000Derivative, Class A CommonForm 4 ↗
David B. WeinerDirector2026-05-20A41,80000Derivative, Class A CommonForm 4 ↗
Ann C. MillerDirector2026-05-20A34,20000Derivative, Class A CommonForm 4 ↗
Ann C. MillerDirector2026-05-20A41,80000Derivative, Class A CommonForm 4 ↗
Jay P. ShepardDirector2026-05-20A41,80000Derivative, Class A CommonForm 4 ↗
Wendy L. YarnoDirector2026-05-20A34,20000Derivative, Class A CommonForm 4 ↗
Wendy L. YarnoDirector2026-05-20A41,80000Derivative, Class A CommonForm 4 ↗
Laurent HumeauChief Scientific Officer2026-05-20A27,44000Derivative, Class A CommonForm 4 ↗
Jay P. ShepardDirector2026-05-20A34,20000Derivative, Class A CommonForm 4 ↗
Michael SumnerChief Medical Officer2026-05-20A37,68400Derivative, Class A CommonForm 4 ↗
Peter KiesCFO2026-05-20A39,76000Derivative, Class A CommonForm 4 ↗
Peter KiesCFO2026-05-20A32,48000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Michael SumnerOption—————$129,554
Jacqueline SheaOption—————351,955
Peter KiesOption—————117,927
Jacqueline SheaPRSU—————346,101
Michael SumnerPRSU—————127,607
Peter KiesPRSU—————117,479
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Michael Sumner$0$0$129,5540.0%
Jacqueline Shea00351,9550.0%
Peter Kies00117,9270.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Jacqueline SheaRSU85,201—$148,250
Jacqueline SheaRSU18,592—32,350
Jacqueline SheaRSU9,960—17,330
Peter KiesOption19,5251.94—
Jacqueline SheaOption52,8241.94—
Michael SumnerRSU2,385—4,150
Jacqueline SheaRSU37,263—64,838
Michael SumnerOption13,33320.76—
Jacqueline SheaOption8,33343.44—
Peter KiesOption8,33380.16—
Jacqueline SheaOption34,8668.46—
Michael SumnerOption21,4501.94—
Peter KiesOption8,37440.08—
Peter KiesOption16,06638.64—
Peter KiesRSU26,100—45,414
Jacqueline SheaOption17,43314.88—
Michael SumnerRSU4,984—8,672
Jacqueline SheaOption8,735133.2—
Michael SumnerRSU10,019—17,433
Peter KiesRSU10,019—17,433
Peter KiesRSU4,984—8,672
Peter KiesRSU2,670—4,646
Michael SumnerRSU2,670—4,646
Michael SumnerOption9,3748.46—
Peter KiesOption9,3748.46—
Jacqueline SheaRSU84,888—147,705
Michael SumnerRSU34,650—60,291
Peter KiesRSU31,900—55,506
Michael SumnerRSU28,350—49,329
Jacqueline SheaRSU17,744—30,875
Peter KiesRSU4,771—8,302
Michael SumnerRSU4,292—7,468
Jacqueline SheaOption23,52438.64—
Jacqueline SheaOption25,78329.88—
Michael SumnerOption2,34314.88—
Peter KiesOption5,62584.24—
Peter KiesOption10,54151.48—
Peter KiesOption4,68714.88—
05

Incentive-plan design — the Compensation Discussion & Analysis

We design our executive compensation program to achieve the following objectives: Motivate and reward executives whose knowledge, skills and performance are essential to our success; Align the performance of our executives and the interests of our stockholders; Recruit and retain executive talent; and Support the corporate business strategy and business plan by rewarding achievement based on our expectations for results and attainment of short-term and long-term goals by our executives.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAon (Human Capital Solutions practice)
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2021,500,9991,607,592470,78791.19%Passed
20252025-05-207,853,0031,058,436152,28586.64%Passed
20242024-05-213,001,768946,999111,74473.93%Passed
20232023-05-1660,418,59232,244,8081,210,46165.2%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2091.19%a
20252025-05-2086.64%b
20242024-05-2173.93%c

a. Approved under the standard stated in the filing — “Abstentions could prevent the approval of Proposal 3 because they do not count as affirmative votes and therefore have the same effect as votes against.”.

b. Approved under the standard stated in the filing — “Abstentions could prevent the approval of Proposal 3 because they do not count as affirmative votes and therefore have the same effect as votes against.”.

c. Approved under the standard stated in the filing — “Abstentions could prevent the approval of Proposal 3 because they do not count as affirmative votes and therefore have the same effect as votes against.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)—
CEO total compensation—
Median employee compensation—
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Simon X. BenitoIndependent · Board Chair · Audit · Nominating/Governance (Chair)$117,500$0$0——$117,500
Ann C. MillerIndependent · Compensation67,50000—24,25091,750
Wendy L. YarnoIndependent · Compensation (Chair) · Nominating/Governance82,50000——82,500
Jay P. ShepardIndependent · Audit · Nominating/Governance80,00000——80,000
Lota S. ZothIndependent · Audit (Chair)77,50000——77,500
Roger D. DanseyIndependent · Nominating/Governance72,09500——72,095
David B. WeinerIndependent · Compensation52,50000——52,500
Jacqueline E. SheaEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 15,000
Stock ownership guideline$135,000
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$549,595
Equity awards (grant-date value)$0
All other compensation$24,250
Total cost of the board$573,845

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Inovio Pharmaceuticals2025Jacqueline Shea$728,000$346,101$351,955$144,144$1,587,155

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Inovio Pharmaceuticals in fiscal 2025?
As disclosed, Jacqueline Shea (President, Chief Executive Officer and Director) was the highest-paid executive at Inovio Pharmaceuticals in fiscal 2025, with total compensation of $1,587,155.
How does Inovio Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Jacqueline Shea's total compensation ranked at the 20th percentile of Inovio Pharmaceuticals's disclosed peer group.
How did shareholders vote on Inovio Pharmaceuticals's executive compensation?
As disclosed, 91.19% of shareholders supported Inovio Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Inovio Pharmaceuticals spend in total on board compensation for fiscal 2025?
As disclosed, Inovio Pharmaceuticals reported total board compensation of $573,845 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jacqueline SheaDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table”. As printed: 1,587,155. Filing ↗machine: r4 · c24 · span 548358–548367
2Section 01, Michael SumnerDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table”. As printed: 910,636. Filing ↗machine: r7 · c24 · span 554768–554775
3Section 01, Peter KiesDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table”. As printed: 833,684. Filing ↗machine: r10 · c24 · span 561102–561109
4Section 03, Michael Sumner OptionDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t120 · r7 · c8 · span 553888–553895
5Section 03, Jacqueline Shea OptionDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t120 · r4 · c8 · span 547327–547334
6Section 03, Peter Kies OptionDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t103 · r6 · c1 · span 472589–472596
7Section 03, Jacqueline Shea PRSUDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t120 · r4 · c6 · span 546983–546990
8Section 03, Michael Sumner PRSUDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t120 · r7 · c6 · span 553594–553601
9Section 03, Peter Kies PRSUDEF 14A2026-04-070001055726-26-000011Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t103 · r6 · c3 · span 473138–473145
10Section 07, pay ratio10-K2026-03-120001055726-26-000008Section “CEO Pay Ratio”. As printed: —. Filing ↗
11Section 08, Simon X. BenitoDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 117,500. Filing ↗machine: t81 · r4 · c1 · span 356565–356805
12Section 08, Ann C. MillerDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 91,750. Filing ↗machine: t81 · r6 · c7 · span 359736–359975
13Section 08, Wendy L. YarnoDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 82,500. Filing ↗machine: t81 · r9 · c1 · span 364470–364709
14Section 08, Jay P. ShepardDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 80,000. Filing ↗machine: t81 · r7 · c1 · span 361303–361542
15Section 08, Lota S. ZothDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 77,500. Filing ↗machine: t81 · r10 · c1 · span 366220–366491
16Section 08, Roger D. DanseyDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 72,095. Filing ↗machine: t81 · r5 · c1 · span 358140–358379
17Section 08, David B. WeinerDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 52,500. Filing ↗machine: t81 · r8 · c1 · span 362903–363142
18Section 08, Jacqueline E. SheaDEF 14A2026-04-070001055726-26-000011Section “Director Compensation”. As printed: 0. Filing ↗
19Section 02, Jacqueline Elizabeth Shea 2026-05-15Form 42026-05-180001771498-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Michael Sumner 2026-05-15Form 42026-05-180001936799-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Michael Sumner 2026-05-15Form 42026-05-180001936799-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Michael Sumner 2026-05-15Form 42026-05-180001936799-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Laurent Humeau 2026-05-15Form 42026-05-180001770390-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Laurent Humeau 2026-05-15Form 42026-05-180001770390-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Laurent Humeau 2026-05-15Form 42026-05-180001770390-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Peter Kies 2026-05-15Form 42026-05-180001259780-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Peter Kies 2026-05-15Form 42026-05-180001259780-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Peter Kies 2026-05-15Form 42026-05-180001259780-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Jacqueline Elizabeth Shea 2026-05-15Form 42026-05-180001771498-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Jacqueline Elizabeth Shea 2026-05-15Form 42026-05-180001771498-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Jacqueline Elizabeth Shea 2026-05-20Form 42026-05-210001771498-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Jacqueline Elizabeth Shea 2026-05-20Form 42026-05-210001771498-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Jacqueline Elizabeth Shea 2026-05-20Form 42026-05-210001771498-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Jacqueline Elizabeth Shea 2026-05-20Form 42026-05-210001771498-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Jacqueline Elizabeth Shea 2026-05-20Form 42026-05-210001771498-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Peter Kies 2026-05-20Form 42026-05-210001259780-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Peter Kies 2026-05-20Form 42026-05-210001259780-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Peter Kies 2026-05-20Form 42026-05-210001259780-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Michael Sumner 2026-05-20Form 42026-05-210001936799-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Michael Sumner 2026-05-20Form 42026-05-210001936799-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Michael Sumner 2026-05-20Form 42026-05-210001936799-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Michael Sumner 2026-05-20Form 42026-05-210001936799-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Laurent Humeau 2026-05-20Form 42026-05-210001770390-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Laurent Humeau 2026-05-20Form 42026-05-210001770390-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Laurent Humeau 2026-05-20Form 42026-05-210001770390-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Laurent Humeau 2026-05-20Form 42026-05-210001770390-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Simon X. Benito 2026-05-20Form 42026-05-210001273306-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Simon X. Benito 2026-05-20Form 42026-05-210001273306-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Roger D. Dansey 2026-05-20Form 42026-05-210001741836-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Roger D. Dansey 2026-05-20Form 42026-05-210001741836-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Lota S. Zoth 2026-05-20Form 42026-05-210001278219-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Lota S. Zoth 2026-05-20Form 42026-05-210001278219-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, David B. Weiner 2026-05-20Form 42026-05-210001669080-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, David B. Weiner 2026-05-20Form 42026-05-210001669080-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Ann C. Miller 2026-05-20Form 42026-05-210001771423-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Ann C. Miller 2026-05-20Form 42026-05-210001771423-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Jay P. Shepard 2026-05-20Form 42026-05-210001587788-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Wendy L. Yarno 2026-05-20Form 42026-05-210001181186-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Wendy L. Yarno 2026-05-20Form 42026-05-210001181186-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Laurent Humeau 2026-05-20Form 42026-05-210001770390-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Jay P. Shepard 2026-05-20Form 42026-05-210001587788-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Michael Sumner 2026-05-20Form 42026-05-210001936799-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Peter Kies 2026-05-20Form 42026-05-210001259780-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Peter Kies 2026-05-20Form 42026-05-210001259780-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
65Section 06, 2026 voteForm 8-K2026-05-200001193125-26-232524Item 5.07 · say-on-pay result. As reported: 91.19% (votes for as printed: 21,500,999). Filing ↗
66Section 06, 2025 voteForm 8-K2025-05-220001055726-25-000045Item 5.07 · say-on-pay result. As reported: 86.64% (votes for as printed: 7,853,003). Filing ↗
67Section 06, 2024 voteForm 8-K2024-05-280001193125-24-148076Item 5.07 · say-on-pay result. As reported: 73.93% (votes for as printed: 3,001,768). Filing ↗
68Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
69Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
70Section 09b board cost (computed)Computed——Cash 549,595 + equity 0 + all other 24,250 = 573,845, summed across the director compensation table rows.machine: formula: Σ = 573,845
71Inovio Pharmaceuticals (subject), Section 10b CEO totalDEF 14A2026-04-070001055726-26-000011CEO total compensation as printed in Inovio Pharmaceuticals's own proxy. As printed: 1,587,155. Filing ↗machine: r4 · c24 · span 548358–548367

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.